☆ 4.6 Editorial Material

Caveats to aggressive lowering of lipids by specific statins

INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)

Journal

INTERNATIONAL JOURNAL OF CARDIOLOGY

Volume 154, Issue 2, Pages 97-101

Publisher

ELSEVIER IRELAND LTD

DOI: 10.1016/j.ijcard.2011.09.002

Keywords

Statins; Diabetes mellitus; Cardiovascular diseases; Adverse effects

Categories

Cardiac & Cardiovascular Systems

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Cardiac & Cardiovascular Systems

Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes Mellitus: an Umbrella review of systematic reviews

Clyve Yu Leon Yaow, Bryan Chong, Yip Han Chin, Martin Tze Wah Kueh, Cheng Han Ng, Kai En Chan, Ansel Shao Pin Tang, Charlotte Chung, Rachel Goh, Gwyneth Kong, Mark Muthiah, Indah Sukmawati, Antonia Anna Lukito, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mamas A. Mamas, Georgios K. Dimitriadis, Nicholas W. S. Chew

Summary: Previous studies have shown that females with type 2 diabetes mellitus (T2DM) may have excess mortality risk compared to their male counterparts. This umbrella review demonstrates that females with T2DM have a higher risk of cardiovascular outcomes than their male counterparts.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study

Ronald B. Goldberg, Trevor J. Orchard, Jill P. Crandall, Edward J. Boyko, Matthew Budoff, Dana Dabelea, Kishore M. Gadde, William C. Knowler, Christine G. Lee, David M. Nathan, Karol Watson, Marinella Temprosa

Summary: The study found that neither lifestyle intervention nor metformin reduced the incidence of major cardiovascular events over a 21-year period, despite their long-term diabetes prevention effects. It is possible that the provision of group lifestyle intervention to all participants, extensive use of statin and antihypertensive agents outside the study, and a decrease in the use of study metformin over time may have diluted the effects of these interventions.

CIRCULATION (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes

Julita Tokarek, Emilian Budny, Maciej Saar, Kamila Stanczak, Ewa Wojtanowska, Ewelina Mlynarska, Jacek Rysz, Beata Franczyk

Summary: Cardiovascular diseases and diabetes mellitus have high morbidity and mortality rates, and they are closely linked with inflammation playing a significant role. SGLT-2 inhibitors and GLP-1 receptor agonists have a positive impact on both diseases. Furthermore, the composition of the gut microbiota can affect the progression of these conditions.

BIOMEDICINES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus

Morten Malmborg, Michelle D. S. Schmiegelow, Thomas Gerds, Morten Schou, Caroline Kistorp, Christian Torp-Pedersen, Gunnar Gislason

Summary: This study demonstrates that primary prevention with statins can reduce the risk of cardiovascular events or death in low-risk patients with T2D, with the greatest benefit seen in elderly patients and those with high adherence to statin treatment.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Pharmacology & Pharmacy

Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study

Mikkel Hojlund, Christina Blanner Wagner, Rikke Wesselhoeft, Kjeld Andersen, Anders Fink-Jensen, Jesper Hallas

Summary: This study found that low-dose chlorprothixene use is associated with increased risk of diabetes and cardiovascular adverse events compared with low-dose quetiapine use.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)

Add to Collection

Review Environmental Sciences

The Associations between Organophosphate Pesticides (OPs) and Respiratory Disease, Diabetes Mellitus, and Cardiovascular Disease: A Review and Meta-Analysis of Observational Studies

Lei Zhao, Qisijing Liu, Yaning Jia, Huishu Lin, Yuanyuan Yu, Xuemei Chen, Ziquan Liu, Weixia Li, Tao Fang, Wenbing Jiang, Jianfeng Zhang, Huanhuan Cui, Penghui Li, Hongyu Li, Shike Hou, Liqiong Guo

Summary: This review and meta-analysis investigated the associations between exposure to organophosphate pesticides (Ops) and respiratory diseases, diabetes mellitus (DM), and cardiovascular diseases (CVDs). The results showed a significant positive association between OP exposure and respiratory diseases and DM, but no significant association with CVD.

TOXICS (2023)

Add to Collection

Article Nutrition & Dietetics

Coffee Consumption and Incidence of Cardiovascular and Microvascular Diseases in Never-Smoking Adults with Type 2 Diabetes Mellitus

Yu-Jie Liu, Meng-Yuan Miao, Jia-Min Wang, Quan Tang, Wen-Wen Han, Yi-Ping Jia, Hao-Wei Tao, Yan Zheng, Rob M. van Dam, Li-Qiang Qin, Guo-Chong Chen

Summary: The relationship between coffee consumption and diabetes-related vascular complications is examined in this study. Moderate coffee consumption (2-4 cups/day) is associated with a lower risk of various cardiovascular diseases and chronic kidney disease in individuals with type 2 diabetes who have never smoked.

NUTRIENTS (2023)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

The effects of severe periodontitis on arterial stiffness using cardio-ankle vascular index in patients with type 2 diabetes

Gizem Torumtay Cin, Semin Melahat Fenkci, Ismail Dogu Kilic, Halil Serdar Aslan, Cihan Ilyas Sevgican, Hande Senol

Summary: This study investigated the association between severe periodontitis and cardiovascular-ankle vascular index (CAVI) in patients with short-term diabetes. The findings suggest that severe periodontitis may act as an intermediate factor between type 2 diabetes and cardiovascular disease by increasing arterial stiffness.

JOURNAL OF PERIODONTAL RESEARCH (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Association of Uncontrolled Hypertension or Diabetes Mellitus With Major Adverse Cardiovascular Events and Mortality in South Korea: Population-Based Cohort Study

Sung-Hee Oh, Dohyang Kim, Jinseub Hwang, Jae-Heon Kang, Yeongkeun Kwon, Jin-Won Kwon

Summary: This study aimed to investigate the association between uncontrolled hypertension or diabetes and the incidence of cardiovascular events or deaths. The study found high rates of uncontrolled hypertension or diabetes, regardless of medication prescription. It suggests the need for a novel system, such as a community-wide management program using mobile health technology, for effective blood pressure or glycemic control.

JMIR PUBLIC HEALTH AND SURVEILLANCE (2023)

Add to Collection

Review Biology

Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases

Danial Khayatan, Seyed Mehrad Razavi, Zahra Najafi Arab, Maryam Khanahmadi, Saeideh Momtaz, Alexandra E. Butler, Fabrizio Montecucco, Yuliya V. Markina, Amir Hossein Abdolghaffari, Amirhossein Sahebkar

Summary: This research summarizes the impact of statins on SIRT proteins and their correlation with cardiovascular diseases, providing a foundation for further investigation in this field.

LIFE-BASEL (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population

Zubair Hussain, Junaid Iqbal, Hongcai Liu, Hou-De Zhou

Summary: A high level of lipoprotein (a) in the plasma is associated with cardiovascular diseases and is considered an independent predictor of certain diseases. Recent studies have shown that the concentration levels of Lp(a) in the Chinese population differ from other populations. In China, higher levels of Lp(a) are linked to an increased risk of various cardiovascular diseases, including coronary heart disease, aortic valve stenosis, thrombosis, and stroke. Additionally, Lp(a) might also play a role in metabolic syndrome, type 2 diabetes, and cancers.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2023)

Add to Collection

Article Endocrinology & Metabolism

Increased Risk of Cardiovascular Disease and Mortality in Patients with Diabetes and Coexisting Depression: A Nationwide Population-Based Cohort Study

Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Yang-Hyun Kim, Eun-Jung Rhee, Won-Young Lee

Summary: Studies have shown that comorbid depression in patients with diabetes increases the risk of cardiovascular disease and mortality. It is important to pay more attention to diabetic patients with depressive symptoms.

DIABETES & METABOLISM JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism

Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study

Minji Sohn, Eun Ju Chun, Soo Lim

Summary: In this 7-year extension study, cilostazol treatment showed effectiveness in reducing cardiovascular events in patients with subclinical coronary artery disease, suggesting the beneficial role of cilostazol in primary prevention of cardiovascular disease.

JOURNAL OF DIABETES (2022)

Add to Collection

Review Endocrinology & Metabolism

Blood Pressure Target in Type 2 Diabetes Mellitus

Hyun-Jin Kim, Kwang-il Kim

Summary: This review discusses the optimal blood pressure targets for patients with diabetes mellitus and summarizes the recommendations from different guidelines. A target blood pressure of <140/90 mm Hg is recommended, and <130/80 mm Hg for patients with diabetes mellitus who have high-risk clinical features.

DIABETES & METABOLISM JOURNAL (2022)

Add to Collection

Article Urology & Nephrology

Changes in metabolic parameters and adverse kidney and cardiovascular events during glomerulonephritis and renal vasculitis treatment in patients with and without diabetes mellitus

Cynthia C. Lim, Jason C. J. Choo, Hui Zhuan Tan, Irene Y. J. Mok, Yok Mooi Chin, Choong Meng Chan, Keng Thye Woo

Summary: The study revealed that diabetes mellitus has a significant impact on kidney failure and cardiovascular events in patients with glomerulonephritis.

KIDNEY RESEARCH AND CLINICAL PRACTICE (2021)

Add to Collection

Article Endocrinology & Metabolism

Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register

Lee-Ling Lim, Eric S. H. Lau, Johnny T. K. Cheung, Siew Pheng Chan, Linong Ji, Soo Lim, Sirinart Sirinvaravong, A. G. Unnikrishnan, Andrea O. Y. Luk, Viviana Cortese, Alexandra Durocher, Juliana C. N. Chan

Summary: This study explored the usage patterns of oral glucose-lowering drugs (OGLDs), particularly sulphonylureas (SUs), in Asian patients with type 2 diabetes (T2D). The findings showed that SUs, often combined with metformin, are a popular class of OGLDs in Asia. They are associated with good glycemic control and safety profiles.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Effect of Lactobacillus plantarum LMT1-48 on Body Fat in Overweight Subjects: A Randomized, Double- Blind, Placebo-Controlled Trial

Minji Sohn, Hyeyoung Jung, Woo Shun Lee, Tai Hoon Kim, Soo Lim

Summary: This study investigated the potential use of Lactobacillus plantarum strain LMT1-48 as a probiotic supplement for overweight individuals. A randomized, double-blind, placebo-controlled clinical trial was conducted on 100 volunteers with a body mass index (BMI) of 25 to 30 kg/m2. The results showed that administration of LMT1-48 significantly reduced body weight, abdominal visceral fat area, insulin resistance, and leptin levels.

DIABETES & METABOLISM JOURNAL (2023)

Add to Collection

Article Endocrinology & Metabolism

Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study

Seon Mee Kang, Han Mi Yun, Minji Sohn, Soo Lim

Summary: In patients with inadequately controlled type 2 diabetes treated with metformin and sulphonylurea, ipragliflozin showed better glycemic control and metabolic benefits compared to sitagliptin. Ipragliflozin treatment resulted in a significant decrease in glycated hemoglobin levels, improved glucose and fat metabolism, and enhanced vascular function. Both ipragliflozin and sitagliptin were found to be safe.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study

Seung Min Chung, Jun Sung Moon, Jun Hwa Hong, In-Chang Hwang, Soo Lim

Summary: The aim of this study was to investigate the effects of gemigliptin on cardiac function and compare its effects with glimepiride in patients with type 2 diabetes. The results showed that gemigliptin and glimepiride both significantly reduced HbA1c levels without a significant difference between the groups. Gemigliptin also had positive effects on insulin resistance, inflammatory markers, lipid profiles, and body composition. No significant changes in cardiac biomarkers were observed. The study received a score of 8 out of 10.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Effect of olmesartan and amlodipine on serum angiotensin-(1-7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension

Kyuho Kim, Ji Hye Moon, Chang Ho Ahn, Soo Lim

Summary: This study suggests that olmesartan has beneficial effects on serum ACE2 and Ang-(1-7) levels, as well as kidney and vascular function in patients with type 2 diabetes and hypertension.

DIABETOLOGY & METABOLIC SYNDROME (2023)

Add to Collection

Article Endocrinology & Metabolism

Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta-analysis

Yingying Luo, Jun Xia, Zhan Zhao, Yaping Chang, Yong Mong Bee, Khue Thy Nguyen, Soo Lim, Daisuke Yabe, Margaret McGill, Alice Pik Shan Kong, Siew Pheng Chan, Marisa Deodat, Chaicharn Deerochanawong, Ketut Suastika, Chenchen Xu, Liming Chen, Wei Chen, Xiaoying Li, Weigang Zhao, Xiaomei Yao, Linong Ji

Summary: The study aimed to investigate the effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins in insulin-naive patients with type 2 diabetes mellitus. Meta-analyses and network meta-analyses showed that glargine U-300 or degludec U-100 might be the most effective choices for injecting basal insulin regimens at bedtime, followed by glargine U-100 or detemir, and NPH. Injecting glargine U-100 in the morning may be more effective and result in fewer hypoglycemic events. The optimal starting dose for any basal insulin initiation can be 0.10-0.20 U/kg/day. There is no eligible evidence to determine the optimal maintenance dose for basal insulins.

JOURNAL OF DIABETES (2023)

Add to Collection

Review Endocrinology & Metabolism

Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline

Linong Ji, Yingying Luo, Yong Mong Bee, Jun Xia, Khue Thy Nguyen, Weigang Zhao, Liming Chen, Siew Pheng Chan, Chaicharn Deerochanawong, Soo Lim, Daisuke Yabe, Margaret McGill, Ketut Suastika, Xiaoying Li, Alice Pik Shan Kong, Wei Chen, Zhan Zhao, Chenchen Xu, Marisa Deodat, Xiaomei Yao

Summary: The study aimed to provide recommendations on the use of five basal insulins in insulin-naive adults with type 2 diabetes in the Asia-Pacific region. Through a systematic review and guideline development process, clinical practice guidelines were formulated based on GRADE methods. The guidelines received high agreement rates, and strong and conditional recommendations were made. The recommendations and clinical thresholds set in the guidelines can be valuable references for clinicians worldwide.

JOURNAL OF DIABETES (2023)

Add to Collection

Article Medicine, Research & Experimental

Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors

Jaewon Oh, Wonho Kim, Gee-Hee Kim, Hack-Lyoung Kim, Sang-Don Park, Kyung Wan Min, Dongkeun Hyun, Jun Hwa Hong, Soo Lim, Jinho Shin

Summary: This study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide in South Korean patients with hypertension and cardiovascular risk factors. The results showed that the therapy led to a significant reduction in blood pressure and had a high control rate.

ADVANCES IN THERAPY (2023)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study

Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang Soo Kim, Tae Ho Kim, Kyu Chang Won, Ki Young Lee, Jae Hyoung Cho, Ju Young Han, So Hun Kim, Jae Jin Nah, Hwa Rang Song, Si Eun Lee, Sungrae Kim

Summary: This study compared the efficacy and safety of the novel sodium-glucose cotransporter 2 inhibitor enavogliflozin with dapagliflozin in Korean patients with type 2 diabetes mellitus. The results showed that enavogliflozin and dapagliflozin had similar effects in reducing HbA1c, with no significant difference between the two groups. Additionally, the incidence of treatment-emergent adverse events was comparable between the groups. Therefore, enavogliflozin can be considered an effective treatment option for T2DM.

DIABETES & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials

Minji Sohn, Juan P. Frias, Soo Lim

Summary: The study aimed to investigate the cardiovascular protection and safety of glucose-lowering therapies (GLTs). The results showed that glucagonlike peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and thiazolidinedione therapy can reduce the risk of major adverse cardiovascular events (MACEs). GLP-1 RAs had favorable cardiovascular and renal outcomes, SGLT-2is had significant effects on renal outcomes, and thiazolidinedione therapy increased the risk of heart failure and had no benefits on mortality.

DIABETES OBESITY & METABOLISM (2023)

Add to Collection

Article Endocrinology & Metabolism

Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study

Jun Hwa Hong, Jun Sung Moon, Kayeon Seong, Soo Lim

Summary: This study compared the efficacy and safety of three drugs (sitagliptin, dapagliflozin, and lobeglitazone) in patients with uncontrolled type 2 diabetes. The results showed that all three drugs were effective in controlling blood sugar and had comparable safety profiles. Dapagliflozin therapy, in particular, showed positive effects on improving body composition.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Add to Collection

Article Endocrinology & Metabolism

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage

Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Takahisa Handa, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi

Summary: The hepatoprotective effects of pemafibrate are dominant in patients with type 2 diabetes complicated by liver dysfunction, leading to improvement in liver function and fibrosis.

DIABETOLOGY & METABOLIC SYNDROME (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction

Inho Kim, Hyun-Jai Cho, Soo Lim, Seung Hyeok Seok, Hae-Young Lee

Summary: The sodium-glucose transporters inhibitors empagliflozin and sotagliflozin not only lower glucose but also protect against heart failure, possibly by inhibiting the activity of NHE1.

EXPERIMENTAL AND MOLECULAR MEDICINE (2023)

Add to Collection

Article Health Care Sciences & Services

How to cope with emerging viral diseases: lessons from South Korea?s strategy for COVID-19, and collateral damage to cardiometabolic health

Soo Lim, Minji Sohn

Summary: South Korea implemented active epidemiological investigations, strict isolation measures, and extensive lockdowns to control the spread of COVID-19. The situation changed dramatically with the emergence of the Omicron variant in January 2022. Despite a rapid increase in cases, the government gradually eased preventive strategies based on high vaccine coverage. Currently, the COVID-19 situation in South Korea is improving with a low mortality rate and high vaccine coverage.

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

Add to Collection

Article Peripheral Vascular Disease

Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL- CAD Study

Kiwamu Kamiya, Makoto Takei, Toshiyuki Nagai, Toru Miyoshi, Hiroshi Ito, Yoshihiro Fukumoto, Hitoshi Obara, Tatsuyuki Kakuma, Ichiro Sakuma, Hiroyuki Daida, Satoshi Iimuro, Hiroaki Shimokawa, Takeshi Kimura, Ryozo Nagai, Toshihisa Anzai

Summary: This study investigated the association between non-lipid residual risk factors and cardiovascular events in patients with stable coronary artery disease. The results showed that renal function and glycemic control were independently associated with adverse events, suggesting their importance as non-lipid therapeutic targets.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.